Notably, combinatorial administration of nintedanib and sirolimus (an mTOR inhibitor) rescued the vascular pathology of HHT in both genetic (Alk mutant) and drug-induced (BMP9/10ib treated) mouse models of HHT [204]. The gene discussed is ALK; the disease is hereditary hemorrhagic telangiectasia.